sur Bausch Health Companies Inc. (NASDAQ:BHC)
Bausch Health Considers Potential Sale of Bausch + Lomb
Bausch Health Companies Inc., a global pharmaceutical company, has confirmed it is exploring a possible sale of its subsidiary, Bausch + Lomb. This consideration follows the strategic decision by Bausch Health's Board of Directors to complete the full separation of its eye health division. As of now, this remains one of several options under review, with no definitive transaction decided.
The Canadian Investment Regulatory Organization (CIRO) requested that Bausch Health validate the potential sales process amid market speculation and stock volatility. The company has stated it will not provide further information until appropriate, highlighting the uncertainty surrounding any potential transaction.
Bausch Health continues to be publicly traded on both the New York Stock Exchange and Toronto Stock Exchange. The company emphasizes that these plans are part of ongoing efforts to optimize their strategic operations and overall business model.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Bausch Health Companies Inc.